TheStreet cut shares of Davita (NYSE:DVA) from a b- rating to a c+ rating in a research note released on Thursday morning.

A number of other research analysts have also weighed in on DVA. Zacks Investment Research lowered shares of Davita from a buy rating to a hold rating in a research note on Wednesday, August 1st. JPMorgan Chase & Co. raised shares of Davita from an underweight rating to a neutral rating in a research note on Thursday, September 13th. ValuEngine raised shares of Davita from a hold rating to a buy rating in a research note on Tuesday, October 9th. Raymond James lowered shares of Davita from a strong-buy rating to a market perform rating in a research note on Thursday. Finally, Royal Bank of Canada raised their price objective on shares of Davita from $70.00 to $78.00 and gave the company a sector perform rating in a research note on Thursday. Seven research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Davita currently has a consensus rating of Hold and a consensus target price of $84.75.

NYSE:DVA traded down $0.45 during trading hours on Thursday, reaching $69.70. The company had a trading volume of 2,486,230 shares, compared to its average volume of 1,943,652. The company has a current ratio of 1.90, a quick ratio of 1.88 and a debt-to-equity ratio of 1.82. The stock has a market capitalization of $12.70 billion, a price-to-earnings ratio of 20.99, a PEG ratio of 0.98 and a beta of 1.09. Davita has a twelve month low of $53.78 and a twelve month high of $80.71.

Davita (NYSE:DVA) last released its quarterly earnings data on Wednesday, November 7th. The company reported $0.56 earnings per share for the quarter, missing analysts’ consensus estimates of $0.89 by ($0.33). Davita had a net margin of 5.39% and a return on equity of 13.37%. The business had revenue of $2.85 billion during the quarter, compared to the consensus estimate of $2.93 billion. During the same period last year, the business posted $0.81 earnings per share. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. Equities analysts predict that Davita will post 4 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. United Asset Strategies Inc. lifted its position in shares of Davita by 13.0% during the second quarter. United Asset Strategies Inc. now owns 6,405 shares of the company’s stock valued at $445,000 after purchasing an additional 735 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in shares of Davita by 10.2% during the third quarter. Commonwealth Equity Services LLC now owns 8,168 shares of the company’s stock valued at $585,000 after purchasing an additional 757 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in shares of Davita by 4.5% during the second quarter. Janney Montgomery Scott LLC now owns 19,009 shares of the company’s stock valued at $1,320,000 after purchasing an additional 811 shares in the last quarter. Northstar Group Inc. lifted its position in shares of Davita by 7.8% during the third quarter. Northstar Group Inc. now owns 11,684 shares of the company’s stock valued at $837,000 after purchasing an additional 850 shares in the last quarter. Finally, Vident Investment Advisory LLC lifted its position in shares of Davita by 1.5% during the second quarter. Vident Investment Advisory LLC now owns 57,294 shares of the company’s stock valued at $3,979,000 after purchasing an additional 872 shares in the last quarter. 87.36% of the stock is currently owned by hedge funds and other institutional investors.

About Davita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Story: Find a Trading Strategy That Works

Analyst Recommendations for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.